Literature DB >> 10596704

Human neutrophil lipocalin, a highly specific marker for acute exacerbation in cystic fibrosis.

I Eichler1, M Nilsson, R Rath, I Enander, P Venge, D Y Koller.   

Abstract

Cystic fibrosis (CF) is characterized by the production of abnormally thick secretions in the airways, chronic bacterial endobronchial infections and a chronic, predominantly neutrophilic inflammatory response. Therefore, myeloperoxidase (MPO) and lactoferrin are frequently used as inflammatory markers. Recently, a new protein in the neutrophil granules, human neutrophil lipocalin (HNL) has been discovered. The aim of the present study was to investigate HNL in sera of patients with CF and its relation to MPO and lactoferrin as well as to acute pulmonary exacerbation. Serum concentrations of HNL, MPO and lactoferrin were determined in 42 patients with CF and in 25 healthy subjects. Patients with CF were divided into groups with and without acute pulmonary exacerbation (APE) and also with and without colonization with Pseudomonas aeruginosa (Pa). Median serum levels of HNL (200.5 microg x L(-1)), MPO (595 microg x L(-1)) and lactoferrin (1,356.5 microg x L(-1)) were significantly increased in patients with CF compared to control subjects (57.7, 178 and 478 microg x L(-1), respectively; p<0.0001). CF patients with APE had significantly increased serum concentrations of HNL (321 versus 97.7 microg x L(-1); p<0.0001), MPO (1,125 versus 300 microg x L(-1); p<0.005) and lactoferrin (4,936 versus 980 microg x L(-1); p<0.001) compared with patients in stable clinical condition. Similarly, patients colonized with Pa had significantly higher concentrations of HNL, MPO and lactoferrin than Pa negative patients. These results indicate that in patients with cystic fibrosis, serum concentrations of human neutrophil lipocalin are markedly increased with a strong relationship to myeloperoxidase and lactoferrin. Thus, determination of serum human neutrophil lipocalin concentrations may be another useful diagnostic tool to monitor neutrophil inflammation in cystic fibrosis. The more marked difference in human neutrophil lipocalin compared with myeloperoxidase concentrations with no overlap between patients with acute pulmonary exacerbation and those in stable condition even suggests that human neutrophil lipocalin may be a more sensitive and specific discriminator.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10596704     DOI: 10.1183/09031936.99.14511459

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

1.  Adipocyte-Specific Ablation of PU.1 Promotes Energy Expenditure and Ameliorates Metabolic Syndrome in Aging Mice.

Authors:  Ke Yun Chen; Alejandra De Angulo; Xin Guo; Aditya More; Scott A Ochsner; Eduardo Lopez; David Saul; Weijun Pang; Yuxiang Sun; Neil J McKenna; Qiang Tong
Journal:  Front Aging       Date:  2022-02-02

2.  Expression of S100A12 (EN-RAGE) in cystic fibrosis.

Authors:  D Foell; S Seeliger; T Vogl; H-G Koch; H Maschek; E Harms; C Sorg; J Roth
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

3.  Discrepancy between mRNA and Protein Expression of Neutrophil Gelatinase-Associated Lipocalin in Bronchial Epithelium Induced by Sulfur Mustard.

Authors:  Majid Ebrahimi; Mehryar Habibi Roudkenar; Abbas Ali Imani Fooladi; Raheleh Halabian; Mostafa Ghanei; Hisatake Kondo; Mohammad Reza Nourani
Journal:  J Biomed Biotechnol       Date:  2010-05-20

4.  Diagnostic value of exhaled carbon monoxide as an early marker of exacerbation in children with chronic lung diseases.

Authors:  Karima A Abd El Khalek; Magda Y El Seify; Omneya I Youssef; Mona M Badr
Journal:  ISRN Pediatr       Date:  2012-09-11

5.  Pyoverdine, the Major Siderophore in Pseudomonas aeruginosa, Evades NGAL Recognition.

Authors:  Mary E Peek; Abhinav Bhatnagar; Nael A McCarty; Susu M Zughaier
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-09-02

6.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

7.  Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis.

Authors:  Bradley S Quon; David A Ngan; Pearce G Wilcox; S F Paul Man; Don D Sin
Journal:  PLoS One       Date:  2014-02-20       Impact factor: 3.240

Review 8.  Radiographic contrast-media-induced acute kidney injury: pathophysiology and prophylactic strategies.

Authors:  Umar Sadat
Journal:  ISRN Radiol       Date:  2013-09-16

9.  Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.

Authors:  Rosa Maria Girón-Moreno; José L Justicia; Sara Yamamoto; Claudia Valenzuela; Carolina Cisneros; Rosa Mar Gómez-Punter; Gilda Fernandes-Vasconcelos; Julio Ancochea
Journal:  BMC Pulm Med       Date:  2014-09-23       Impact factor: 3.317

Review 10.  Human neutrophil lipocalin (HNL) as a biomarker of acute infections.

Authors:  Per Venge
Journal:  Ups J Med Sci       Date:  2018-02-23       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.